

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A genetically engineered hybrid polypeptide plasminogen activator comprising: a) wherein said activator comprises a streptokinase (SK) or its functional component containing essentially polypeptide fragment corresponding to residues 16-383 of SK whereby retaining up to 100% plasminogen activity or a catalytically active fragment thereof, and b) at least one the fibronectin finger-type fibrin binding domain (FBD) pairs pair 1-2 or pair 4-5 [1-2 and/or 4-5] of fibronectin or its functional components, bound specifically to N and/or C terminals of a), the SK, with the said activator showing a desired time lag in said hybrid polypeptide effecting plasminogen activation after a time lag due to a plasmin-dependent activation mechanism.

2. Canceled.

3. (Currently Amended) [~~A~~] The hybrid plasminogen activator as claimed in claim 1, wherein the time lag ~~is ranging~~ ranges between 5 to 30 minutes.

4.-31. Canceled.

32. (Currently Amended) A pharmaceutical composition comprising a genetically engineered hybrid polypeptide plasminogen activator of claim 1 or claim 33, and stabilizer(s).

33. (New) The hybrid polypeptide activator as claimed in claim 1 comprising: a) a streptokinase (SK) containing residues 16-383 of SEQ ID NO2, and b) at least one the fibronectin finger-type fibrin binding domain (FBD) pairs 1-2 or 4-5 of SEQ ID NO:4,

Applicant : Rajesh Kumar, et al.
Serial No. : 09/940,235
Filed : August 27, 2001
Page : 4 of 6

Attorney's Docket No.: 07064-009002

said at least one fibronectin finger-type binding domain (FBD) being bound to said streptokinase at its N or at its C-terminus.